Research programme - peptide melanocortin receptor 2 antagonists - Ipsen

Drug Profile

Research programme - peptide melanocortin receptor 2 antagonists - Ipsen

Alternative Names: ACTH receptor antagonists - Ipsen; Adrenocorticotropic hormone receptor antagonists - Ipsen; IRC 274; MC2 receptor antagonists - Ipsen

Latest Information Update: 09 Aug 2016

Price : $50

At a glance

  • Originator Ipsen
  • Class Peptide hormones; Peptides
  • Mechanism of Action Melanocortin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pituitary ACTH hypersecretion

Most Recent Events

  • 01 Apr 2016 Pharmacodynamics data from preclinical studies in Pituitary ACTH Hypersecreation presented at the 98th Annual Meeting of the Endocrine Society (ENDO-2016)
  • 18 Aug 2015 Preclinical development is ongoing in France - Ipsen pipeline Aug 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top